Cargando…
Insulin glargine versus other types of basal insulin–clinical and tumor characteristics in patients with breast carcinoma
BACKGROUND: Recent epidemiological studies have suggested that some insulin analogues could be associated with an increased risk of cancer. The aim of this retrospective study was to examine whether patients with diabetes mellitus (DM) using insulin glargine have a higher tumor stage of breast carci...
Autores principales: | Besic, Nikola, Satej, Nika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852785/ https://www.ncbi.nlm.nih.gov/pubmed/24131755 http://dx.doi.org/10.1186/1756-0500-6-416 |
Ejemplares similares
-
Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics
por: Besic, Nikola, et al.
Publicado: (2014) -
Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
por: Davies, M. J., et al.
Publicado: (2016) -
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021) -
Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018) -
Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)